Antonation K, Patel S, Waddell J Trumble, Poliquin P Guillaume, Alexander D C, Hoang L, Farrell D, Garceau R, Haldane D, Jamieson F, Marchand R, MacKeen A, Marcino D, Theriault S, Tyrrell G J, Zahariadis G, Zelyas N
National Microbiology Laboratory, Winnipeg, MB.
Public Health Ontario, Toronto, ON.
Can Commun Dis Rep. 2017 Jan 5;43(1):25-28. doi: 10.14745/ccdr.v43i01a05.
The advice contained in this document should be read in conjunction with relevant federal, provincial, territorial and local legislation, regulations, and policies. Recommended measures should not be regarded as rigid standards, but principles and recommendations to inform the development of guidance. This advice is based on currently available scientific evidence and adopts a precautionary approach where the evidence is lacking or inconclusive. It was approved for publication on December 5, 2016. It is subject to review and change as new information becomes available. The main changes to this version include additions to: Case load reported to date, Sarcoidosis-like disease as an Indicator, Whole Genome Sequencing effort, links to Provincial and Territorial Lab Services and Health Canada reporting.
本文件中的建议应结合相关联邦、省、地区及地方法规、条例和政策一并阅读。推荐措施不应被视为严格标准,而是为制定指南提供参考的原则和建议。本建议基于当前可得的科学证据,并在证据不足或不确定时采用预防措施。它于2016年12月5日批准发布。随着新信息的出现,它将接受审查并可能更改。此版本的主要更改包括增加了:迄今报告的病例数、类结节病作为一项指标、全基因组测序工作、与省级和地区实验室服务的链接以及向加拿大卫生部报告的内容。